Online citations, reference lists, and bibliographies.
← Back to Search

A Look To Future Directions In Gene Therapy Research For Monogenic Diseases

M. Porteus, Jon P. Connelly, Shondra M Pruett
Published 2006 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
The concept of gene therapy has long appealed to biomedical researchers and clinicians because it promised to treat certain diseases at their origins. In the last several years, there have been several trials in which patients have benefited from gene therapy protocols. This progress, however, has revealed important problems, including the problem of insertional oncogenesis. In this review, which focuses on monogenic diseases, we discuss the problem of insertional oncogenesis and identify areas for future research, such as developing more quantitative assays for risk and efficacy, and ways of minimizing the genotoxic effects of gene therapy protocols, which will be important if gene therapy is to fulfill its conceptual promise.
This paper references
10.1162/001152605774431446
Limiting science: a biologist's perspective
D. Baltimore (2005)
10.1002/jgm.891
Phage ϕC31 integrase‐mediated genomic integration of the common cytokine receptor gamma chain in human T‐cell lines
Y. Ishikawa (2006)
10.1016/J.YMTHE.2005.04.006
Gene targeting with viral vectors.
P. Hendrie (2005)
In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery.
P. Held (2005)
10.1126/SCIENCE.1088757
Gene Targeting in Stem Cells from Individuals with Osteogenesis Imperfecta
J. Chamberlain (2004)
10.1016/S0065-2660(05)54008-2
Site-specific integration with phiC31 integrase for prolonged expression of therapeutic genes.
D. S. Ginsburg (2005)
10.1038/nm1393
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1
M. Ott (2006)
10.1126/SCIENCE.1091667
Gene Therapy Insertional Mutagenesis Insights
Utpal P. Davé (2004)
10.1038/nature03845
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants
M. Hemann (2005)
10.1126/SCIENCE.1078395
Chimeric Nucleases Stimulate Gene Targeting in Human Cells
M. Porteus (2003)
10.1016/J.JMB.2005.11.098
Integration specificity of phage phiC31 integrase in the human genome.
Thomas W. Chalberg (2006)
10.1146/ANNUREV.BIOCHEM.74.050304.091637
Gene therapy: twenty-first century medicine.
I. Verma (2005)
10.1016/S0140-6736(04)17590-9
Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector
H. Gaspar (2004)
Phage phiC31 integrase-mediated genomic integration of the common cytokine receptor gamma chain in human T-cell lines.
Y. Ishikawa (2006)
10.1101/SQB.1980.044.01.099
Origin and function of avian retrovirus transforming genes.
J. Bishop (1980)
10.1073/PNAS.160159597
A chromatin insulator protects retrovirus vectors from chromosomal position effects.
D. W. Emery (2000)
10.1128/MCB.23.10.3558-3565.2003
Efficient Gene Targeting Mediated by Adeno-Associated Virus and DNA Double-Strand Breaks
M. Porteus (2003)
10.1182/BLOOD-2005-01-0178
Drug therapy for acute myeloid leukemia.
M. Tallman (2005)
AAVmediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia
CS Manno (2003)
Gene therapy insertional mutagenesis
UP Dave (2004)
10.1016/j.ymthe.2004.11.001
In Vivo Correction of Murine Hereditary Tyrosinemia Type I by ϕC31 Integrase-Mediated Gene Delivery.
P. Held (2005)
10.1038/bjc.1969.41
The two "hit" and multiple "hit" theories of carcinogenesis.
D. Ashley (1969)
10.1093/NAR/29.24.5044
Directed evolution of a recombinase for improved genomic integration at a native human sequence.
C. R. Sclimenti (2001)
10.1016/S0065-2660(05)54009-4
Sleeping beauty transposon-mediated gene therapy for prolonged expression.
P. Hackett (2005)
10.1016/0168-9525(96)10019-6
Genetic manipulation of genomes with rare-cutting endonucleases.
M. Jasin (1996)
10.1038/nrmicro1263
Genome-wide analysis of retroviral DNA integration
F. Bushman (2005)
10.1016/j.ymthe.2005.07.694
Report from the 2nd Stem Cell Clonality and Genotoxicity Retreat: St. Louis, MO, June 1, 2005.
R. Frederickson (2005)
10.1016/S0092-8674(00)81333-1
Lessons from Hereditary Colorectal Cancer
K. Kinzler (1996)
10.1038/nm766
Stable nonviral genetic correction of inherited human skin disease
S. Ortiz-Urda (2002)
10.1038/nm1358
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response
C. Manno (2006)
10.1002/gcc.10199
Prenatal origin of TEL‐AML1–positive acute lymphoblastic leukemia in children born in California
C. McHale (2003)
10.1073/PNAS.93.3.1156
Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain.
Y. Kim (1996)
10.1038/ng824
Chromosomal effects of adeno-associated virus vector integration
D. Miller (2002)
10.1016/J.YMTHE.2005.07.358
Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice.
M. Themis (2005)
10.1534/genetics.105.052829
Efficient Gene Targeting in Drosophila With Zinc-Finger Nucleases
K. Beumer (2006)
Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin.
C. May (2000)
10.1126/SCIENCE.1070104
Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning
A. Aiuti (2002)
10.1089/10430340152712719
A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency.
S. Raper (2002)
10.1016/J.YMGME.2003.08.016
Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer.
S. Raper (2003)
Sleeping beauty PLoS Genetics | www.plosgenetics.org September 2006 | Volume 2 | Issue 9 | e133 1291 transposon-mediated gene therapy for prolonged expression
PB Hackett (2005)
10.1182/BLOOD-2002-10-3296
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.
C. Manno (2003)
10.1542/peds.2006-0900BBBB
Gene Therapy of X-Linked Severe Combined Immunodeficiency by Use of a Pseudotyped Gammaretroviral Vector
E. Simons (2006)
10.1073/PNAS.68.4.820
Mutation and cancer: statistical study of retinoblastoma.
A. Knudson (1971)
Evasion of the p 53 tumour surveillance network by tumourderived MYC mutants
MT Hemann (2005)
10.1002/path.1896
Viral gene therapy strategies: from basic science to clinical application
L. Young (2006)
10.1038/NG0498-325
Human gene targeting by viral vectors
D. W. Russell (1998)
10.1093/HMG/DDL061
Sleeping beauty: a novel cancer gene discovery tool.
A. Dupuy (2006)
10.1093/nar/gki912
Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells
S. Durai (2005)
10.1182/BLOOD-2002-01-0219
Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo.
D. W. Emery (2002)
10.1016/S0092-8674(02)00864-4
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
A. W. Schröder (2002)
10.1038/35017565
Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin
C. May (2000)
10.1128/JVI.79.17.11434-11442.2005
Large-Scale Analysis of Adeno-Associated Virus Vector Integration Sites in Normal Human Cells
D. Miller (2005)
10.1038/nature03556
Highly efficient endogenous human gene correction using designed zinc-finger nucleases
Fyodor D. Urnov (2005)
10.1073/PNAS.86.1.227
Positive genetic selection for gene disruption in mammalian cells by homologous recombination.
J. Sedivy (1989)
10.1038/sj.bjc.6600601
Presence of clone-specific markers at birth in children with acute lymphoblastic leukaemia
L. Hjalgrim (2002)
10.1038/nrg1066
Progress and problems with the use of viral vectors for gene therapy
C. Thomas (2003)
10.1038/nbt753
Site-specific genomic integration produces therapeutic Factor IX levels in mice
E. Olivares (2002)
10.1128/MCB.23.10.3550-3557.2003
Human Gene Targeting by Adeno-Associated Virus Vectors Is Enhanced by DNA Double-Strand Breaks
D. Miller (2003)
10.1073/pnas.0507496103
Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells
Alessandra Recchia (2006)
10.1146/ANNUREV.MED.56.090203.104142
Gene therapy for severe combined immunodeficiency.
M. Cavazzana‐Calvo (2005)
10.1016/S0092-8674(02)00681-5
Correction of a Genetic Defect by Nuclear Transplantation and Combined Cell and Gene Therapy
W. Rideout (2002)
10.1038/4401123A
Gene therapy: Therapeutic gene causing lymphoma
N. Woods (2006)
10.1038/nrc795
Modelling the molecular circuitry of cancer
W. Hahn (2002)
10.1182/BLOOD-2004-04-1427
Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector.
G. Puthenveetil (2004)
10.1101/GAD.954702
Insulators: many functions, many mechanisms.
A. G. West (2002)



This paper is referenced by
Investigation of the effects of virus integration on host gene expression in mouse tumour samples
Emma Osejindu (2011)
10.1038/gt.2009.55
Visualization of in vivo electroporation-mediated transgene expression in experimental tumors by optical and magnetic resonance imaging
W. Aung (2009)
10.1038/mt.2010.23
Expression of dog microdystrophin in mouse and dog muscles by gene therapy.
Christophe Pichavant (2010)
The role of cytoskeletal tropomyosins in skeletal muscle and muscle disease
Nicole Vlahovich (2007)
10.1016/b978-0-12-374194-3.00001-9
A History of Drug Discovery
F. Chast (2008)
10.3892/OL_00000032
Recombinant adeno-associated viruses (rAAV2) facilitate the intraperitoneal gene delivery to cancer cells.
M. Małecki (2010)
10.1111/j.1610-0387.2010.07435_supp.x
Vektoren für die Gentherapie von Hautkrankheiten
W. Pfützner (2010)
10.17656/JSMC.10018
A SYNTHETIC CELL-PENETRATING PEPTIDE (CPP) WITH PROTAMINE CONJUGATE UTILIZED FOR GENE DELIVERY
Beston Faiek Nore (2012)
10.1038/gt.2008.16
Bioadhesive hyaluronan–chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue
M. Fuente (2008)
Recombinant adeno-associated viruses ( rAAV 2 ) facilitate the intraperitoneal gene delivery to cancer cells
M. Małecki ()
10.1038/SJ.MT.6300366
Transcriptional activities of the Sleeping Beauty transposon and shielding its genetic cargo with insulators.
Oliver Walisko (2008)
10.1201/9780849387999.CH31
Nonviral Genome Modification Strategies for Gene Therapy: Transposon, Integrase, and Homologous Recombination Systems
L. Woodard (2008)
10.1002/jcb.22296
Three‐dimensional porous scaffolds at the crossroads of tissue engineering and cell‐based gene therapy
D. Coutu (2009)
10.4155/fmc.11.139
Towards artificial metallonucleases for gene therapy: recent advances and new perspectives.
B. Gyurcsik (2011)
10.1016/j.ejpb.2010.11.007
Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Melanie Günther (2011)
10.1016/J.ADENGL.2015.04.006
Innovative Therapeutic Strategies for Recessive Dystrophic Epidermolysis Bullosa
F. Larcher (2015)
10.1039/d0tb01177k
A non-viral nano-delivery system targeting epigenetic methyltransferase EZH2 for precise acute myeloid leukemia therapy.
Babita Kaundal (2020)
10.1088/0957-4484/19/7/075105
Design of novel polysaccharidic nanostructures for gene delivery.
M. de la Fuente (2008)
10.2463/MRMS.9.37
Molecular MR imaging of cancer gene therapy: ferritin transgene reporter takes the stage.
S. Hasegawa (2010)
10.3389/fmicb.2014.00250
Cellular unfolded protein response against viruses used in gene therapy
D. Sen (2014)
10.1016/j.pcl.2009.11.004
Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders.
J. Boelens (2010)
10.1007/s00018-007-7206-8
Custom-designed zinc finger nucleases: What is next?
J. Wu (2007)
10.2147/BTT.S3180
α-L-iduronidase therapy for mucopolysaccharidosis type I
J. Tolar (2008)
10.1186/1471-2199-10-98
RAD51 paralogs promote homology-directed repair at diversifying immunoglobulin V regions
Ellen C. Ordinario (2009)
10.1002/term.1656
Co‐transduction of lentiviral and adenoviral vectors for co‐delivery of growth factor and shRNA genes in mesenchymal stem cells‐based chondrogenic system
F. Zhang (2015)
10.1038/jid.2010.249
Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa.
E. Murauer (2011)
10.1007/978-1-59745-483-4_40
Custom-designed molecular scissors for site-specific manipulation of the plant and mammalian genomes.
K. Kandavelou (2009)
10.3390/toxins2112622
Tetanus Toxin C-Fragment: The Courier and the Cure?
J. M. Toivonen (2010)
10.1371/journal.pbio.0050246
Chromatin Structure Regulates Gene Conversion
W. J. Cummings (2007)
10.1038/mt.2011.130
Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis.
Su Xu (2011)
nnovative Therapeutic Strategies for Recessive ystrophic Epidermolysis Bullosa
M. Del Ríoa (2019)
10.1002/9783527669417.CH9
Precision Genome Surgery with Meganucleases: A Promising Biopharmaceutical for Gene Therapy
A. Pingoud (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar